Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.

摘要: Patients with metastatic colorectal cancer have a poor prognosis and present challenge to clinicians. The role of the antiepidermal growth factor receptor (EGFR) pathway in tumorogenesis tumor progression has been well defined. This paper will review use anti-EGFR monoclonal antibodies treatment operable, as both setting KRAS mutation unselected patients later wild-type patients. Active investigations designed further identify predictive biomarkers that may be potentially druggable are reviewed well.